These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27896545)

  • 1. Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study.
    Fleseriu M; Rusch E; Geer EB;
    Endocrine; 2017 Jan; 55(1):247-255. PubMed ID: 27896545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR.
    Samson SL
    Drugs; 2016 Sep; 76(13):1235-1243. PubMed ID: 27473537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of 6 Months' Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings.
    Witek P; Bolanowski M; Szamotulska K; Wojciechowska-Luźniak A; Jawiarczyk-Przybyłowska A; Kałużny M
    Front Endocrinol (Lausanne); 2021; 12():633944. PubMed ID: 33776927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
    Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study.
    Tahara S; Murakami M; Kaneko T; Shimatsu A
    Endocr J; 2017 Jul; 64(7):735-747. PubMed ID: 28592706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pasireotide: a novel treatment for patients with acromegaly.
    Cuevas-Ramos D; Fleseriu M
    Drug Des Devel Ther; 2016; 10():227-39. PubMed ID: 26811671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly.
    Silverstein JM
    Pituitary; 2016 Oct; 19(5):536-43. PubMed ID: 27405306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.
    Shimon I; Adnan Z; Gorshtein A; Baraf L; Saba Khazen N; Gershinsky M; Pauker Y; Abid A; Niven MJ; Shechner C; Greenman Y
    Endocrine; 2018 Nov; 62(2):448-455. PubMed ID: 30051198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study.
    Wolin EM; Hu K; Hughes G; Bouillaud E; Giannone V; Resendiz KH
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):387-95. PubMed ID: 23765178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study.
    Petersenn S; Bollerslev J; Arafat AM; Schopohl J; Serri O; Katznelson L; Lasher J; Hughes G; Hu K; Shen G; Reséndiz KH; Giannone V; Beckers A
    J Clin Pharmacol; 2014 Nov; 54(11):1308-17. PubMed ID: 24800725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.
    Petersenn S; Farrall AJ; De Block C; Melmed S; Schopohl J; Caron P; Cuneo R; Kleinberg D; Colao A; Ruffin M; Hermosillo Reséndiz K; Hughes G; Hu K; Barkan A
    Pituitary; 2014 Apr; 17(2):132-40. PubMed ID: 23529827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.
    Ferolla P; Brizzi MP; Meyer T; Mansoor W; Mazieres J; Do Cao C; Léna H; Berruti A; Damiano V; Buikhuisen W; Grønbæk H; Lombard-Bohas C; Grohé C; Minotti V; Tiseo M; De Castro J; Reed N; Gislimberti G; Singh N; Stankovic M; Öberg K; Baudin E
    Lancet Oncol; 2017 Dec; 18(12):1652-1664. PubMed ID: 29074099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment:
    Feldt-Rasmussen U; Bolanowski M; Zhang SL; Yu Y; Witek P; Kalra P; Kietsiriroje N; Piacentini A; Pedroncelli AM; Samson SL
    Front Endocrinol (Lausanne); 2024; 15():1250822. PubMed ID: 38577574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to Position Pasireotide LAR Treatment in Acromegaly.
    Coopmans EC; Muhammad A; van der Lely AJ; Janssen JAMJL; Neggers SJCMM
    J Clin Endocrinol Metab; 2019 Jun; 104(6):1978-1988. PubMed ID: 30608534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
    Colao A; Bronstein MD; Freda P; Gu F; Shen CC; Gadelha M; Fleseriu M; van der Lely AJ; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Sheppard M;
    J Clin Endocrinol Metab; 2014 Mar; 99(3):791-9. PubMed ID: 24423324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study.
    Chen X; Shen G; Jiang J; Liu H; Hu K; Darstein C; Lasher J; Hu P
    Clin Ther; 2014 Aug; 36(8):1196-210. PubMed ID: 25012727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly.
    Schmid HA; Brue T; Colao A; Gadelha MR; Shimon I; Kapur K; Pedroncelli AM; Fleseriu M
    Endocrine; 2016 Jul; 53(1):210-9. PubMed ID: 26906713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pasireotide Long-Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism.
    Gostelow R; Scudder C; Keyte S; Forcada Y; Fowkes RC; Schmid HA; Church DB; Niessen SJ
    J Vet Intern Med; 2017 Mar; 31(2):355-364. PubMed ID: 28145031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center.
    Pirchio R; Auriemma RS; Vergura A; Pivonello R; Colao A
    J Endocrinol Invest; 2024 Aug; 47(8):1887-1901. PubMed ID: 38532073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pasireotide in Acromegaly: A Review.
    McKeage K
    Drugs; 2015 Jun; 75(9):1039-48. PubMed ID: 26017304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.